|View printer-friendly version|
ASLAN Pharmaceuticals Completes Recruitment for Global Phase 2 Study for Varlitinib in First Line Gastric Cancer
Varlitinib is a potent, reversible, small molecule pan-HER inhibitor and is currently being developed by ASLAN across multiple indications including a global pivotal trial in biliary tract cancer.
Initiated in 2017, the global phase 2/3 study is a double blind, randomised two-arm study that aims to determine the efficacy of varlitinib in combination with mFOLFOX6 (a combination chemotherapy regimen) in comparison to mFOLFOX6 alone in the first line setting. Topline data for the phase 2 study is expected in Q4 2018.
Gastric cancer currently ranks fourth in cancer incidence worldwide1, is the second most common cause of cancer-related deaths worldwide2 and is one of the most common types of cancer in
About varlitinib (ASLAN001)
About ASLAN Pharmaceuticals
Forward looking statements
This release and the accompanying financial information contains forward-looking statements. These statements are based on the current beliefs and expectations of the management of
All statements other than statements of historical fact are forward-looking statements. The words “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. Estimates, projections and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection or forward-looking statement.